Soren Mogelsvang, PhD

President and Chief Executive Officer

Dr. Mogelsvang is a biotech executive and entrepreneur with over 15 years of experience. He is the co-founder of several biotech companies and brings a track record in building and leading privately funded and publicly traded companies. Recent positions he has held include President and CEO of Peak Pharmaceuticals, which he built from concept to a profitable veterinary health company; Co-founder and VP of R&D at Serpin Pharma, a clinical stage biotech company; Co-founder and Head of R&D at Caerus Discovery, an immunology company launched with support from BioWa – Kyowa Hakko Kirin and ImmunoCellular Therapeutics; Head of Cell Biology at ATCC; and Director of Laboratory and Production at Affinity BioReagents. Soren has PhD in Biochemistry (Cambridge, UK), and an MSc in Plant Molecular Biology (University of Copenhagen, Denmark).

Daniele Piomelli, PhD, MD (h.c.)

Chief Scientific Officer

Daniele is an Italian-born American scientist. He studied neuroscience in New York City, with James H. Schwartz and Eric R. Kandel at Columbia University College of Physicians and Surgeons (PhD, 1983-1988) and later with Paul Greengard at the Rockefeller University (Post-doc, 1988-1990). Two of his mentors (ERK and PG) received in 2000 the Nobel Prize for their contributions to medicine. After working at the INSERM in Paris (1990-1995) and at the Neurosciences Institute in La Jolla (1995-1998) with Nobel Laureate Gerald Edelman, he joined the University of California Irvine School of Medicine, where he is now Louise Turner Arnold Chair in Neurosciences and Professor of Anatomy and Neurobiology, Pharmacology and Biological Chemistry. Daniele is scientific cofounder of Kadmus Pharmaceuticals, Thesan Pharmaceuticals and NeoKera.

Richard Paul, MD

Chief Medical Officer

Dr. Paul is a licensed MD with more than two decades of experience in drug development, regulatory affairs and clinical research. His career started with post graduate work at Albert Einstein College of Medicine, Rutgers University’s Internal Medicine Residency program and a Fellowship tenure at Harvard Medical School/Joslin Diabetes Center.  After 9 years of clinical practice, he transitioning into pharmaceutical research with Pfizer and subsequently held executive leadership positions in clinical research, regulatory and medical safety departments with Ergo Science, Grünenthal USA, Shionogi USA and Schering Plough Corporation. Notably, Dr. Paul was the founding Managing Director of Grünenthal USA, establishing the subsidiary for Grünenthal GmbH of Germany. Rich’s experience spans medical safety, clinical research, and regulatory strategy. He has multi-divisional FDA experience having supported a number of Investigational and New Drug Applications with the US FDA and other international regulatory agencies.